Age-associated cognitive impairment, supplemental therapy in cortical myoclonus.

Piracetam acts on the CNS and has been described as a `nootropic'; it is said to protect the cerebral cortex against hypoxia. It is also reported to inhibit platelet aggregation and reduce blood viscosity at high doses.

high distribution in cerebrospinal fluid; not metabolized in the body; primarily excreted unchanged in the urine; Elimination Half-life: 5 to 6 hrs in normal renal function. Piracetam removed by H/D: 50-60%.

Previous hypersensitivity to piracetam, Huntington's chorea, cerebral hemorrhage, End stage renal disease.

Animal studies do not indicate direct or indirect harmful effects.

Piracetam crosses the placental barrier and is excreted in human breast milk.

insomnia, somnolence, weight gain, hyperkinesia, nervousness, and depression.

Orally, age-associated cognitive impairment: 1.2~2.4 g daily. Cortical myoclonus: 7.2 g daily in 2 or 3 divided doses, increasing by 4.8 g daily every 3 or 4 days up to a maximum of 24 g daily.